Patent Assignment
Reel/Frame 014038/0964
Change of Name
Recorded: 2003-05-14
Received: 2003-05-19
Pages: 6
Assignor
AMERICAN CYANAMID COMPANY
Executed: 2002-12-31
Assignee
WYETH HOLDINGS CORPORATION
FIVE GIRALDA FARMS, MADISON, NJ, 07940, UNITED STATES
Covered Properties
(40)
Antifungal antibiotics
Application:
60/436,039 →
Antibiotic cyan426-A
Application:
60/434,005 →
Antibiotics Cyan-416 A, Cyan-416 B, Cyan-416 C, Cyan-416 D, and Cyan-416 E, and ester derivatives of Cyan-416 B
Application:
60/434,004 →
Qs-21 and Il-12 as an Adjuvant Combination
Application:
10/311,422 →
Modified Morbillivirus V Proteins
Application:
10/311,582 →
Method of Enhancing Responses to Herpes Simplex Virus Vaccine
Application:
10/169,057 →
3-Cyanoquinolines as Inhibitors of Egf-R and HER2 Kinases
Application:
10/305,438 →
Allenic Aryl Sulfonamide Hydroxamic Acids as Matrix Metalloproteinase and Tace Inhibitors
Application:
10/285,940 →
Antibiotic cytosporacin
Application:
60/418,605 →
Stabilized pharmaceutical composition containing basic excipient
Application:
60/417,804 →
Process for preparing monoprotected diols from symmetric diols
Application:
60/415,880 →
Novel Methods for Rescue of Rna Viruses
Application:
10/261,961 →
Method of treating resistant tumors
Application:
60/411,883 →
Process for the synthesis of intermediates useful for the synthesis of tublin inhibitors
Application:
60/412,024 →
3-Substituted-3-(Substitutedsulfonyl or Sulfanyl)Pyrroldine-2,5-Diones Useful for Inhibition of Farnesyl-Protein Transferase
Application:
10/227,215 →
5-(Substituted)-5-(Substitutedsulfonyl or Sulfanyl) Thiazolidine-2,4-Diones Useful for Inhibition of Farnesyl-Protein Transferase
Application:
10/226,880 →
5-Substituted-3(2H)-Furanones Useful for Inhibition of Farnesyl-Protein Transferase
Application:
10/226,792 →
Method of Using 5-(Arysulfonyl)-, 5-(Arylsulfanyl)-and 5-(Arylsulfanyl)Thiazolidine-2,4-Diones for Inhibition of Farnesyl-Protein Transferase
Application:
10/226,815 →
5-(Arylsulfonyl)-,5-(Arylsulfinyl), and 5-(Arylsulfanyl)-Thiazolidine-2,4-Diones Useful for Inhibition of Farnesyl-Protein Transferase
Application:
10/227,084 →
74-Kilodalton Outer Membrane Protein from Moraxella Catarrhalis
Application:
10/205,972 →
Antibiotics AW998A, AW998B, AW998C and AW998D
Application:
60/395,766 →
N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
Application:
10/185,080 →
Vasopressin Antagonist and Diuretic Combination
Application:
10/162,451 →
Prevention and treatment of type 2 diabetes
Application:
60/376,618 →
Antibiotics Aa-896
Application:
10/132,005 →
Glycopeptide Antibiotics
Application:
10/131,890 →
Antibiotic Aa 896 Analogs
Application:
10/131,938 →
Substantially Pure Glycopeptide Antibotics Ac-98-1; Ac-98-2; Ac-98-3; Ac-98-4 and Ac-98-5
Application:
10/132,012 →
Nucleoside Peptide Antibiotics Og Aa-896
Application:
10/131,939 →
Glycopeptide Antibiotics
Application:
10/131,847 →
Reversal of Multidrug Resistance in Human Colon Carcinoma Cells
Application:
10/086,132 →
Reversal of multidrug resistance in human colon carcinoma cells
Application:
10/086,169 →
Reversal of multidrug resistance in human colon carcinoma cells
Application:
10/086,133 →
Alkynyl Containing Hydroxamic Acid Compounds as Matrix Metalloproteinase/Tace Inhibitors
Application:
10/029,655 →
Diagnostic Imaging Contrast Agents with Extended Blood Retention
Application:
10/034,522 →
Differential Cytotoxicity of Alternative Forms of Rotavirus Nonstructural Protein 4
Application:
10/048,540 →
Alkynyl Containing Hydroxamic Acid Compounds as Matrix Metalloproteinase and Tace Inhibitors
Application:
10/055,502 →
Adjuvant and Vaccine Compositions Containing Monophosphoryl Lipid A
Application:
09/943,028 →
Glycopeptide antibiotics
Application:
60/286,244 →
Method for Preparing Alpha-Sulfonyl Hydroxamic Acid Derivatives
Application:
09/769,107 →